Belzupacap Sarotalocan

Summary

Belzupacap Sarotalocan (CHEMBL4802193) is a phase-3 clinical-stage protein; indicated across 5 conditions including melanoma and uveal melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 5 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802193
Name	Belzupacap Sarotalocan
Type	Protein
Max phase	3

Also known as: Au-011, AU-011, AU011, Belzupacap sarotalocan, Belzupacap serotalocan, Hpv-np au-011, Light-activated au-011, VIRAL NANOPARTICLE CONJUGATES AU-011, Vnc au-011, BELZUPACAP SAROTALOCAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
melanoma	2	MONDO:0005105	EFO:0000756
uveal melanoma	2	MONDO:0006486	EFO:1000616
neoplasm	1	MONDO:0005070	EFO:0000616

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06643884	PHASE2	RECRUITING	Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT03052127	PHASE1/PHASE2	COMPLETED	Study in Subjects With Small Primary Choroidal Melanoma
NCT04417530	PHASE2	COMPLETED	Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
NCT05483868	PHASE1	RECRUITING	A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05266430	Not specified	TERMINATED	Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).